Open access
Open access
Powered by Google Translator Translator

RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

19 Jul, 2022 | 12:57h | UTC

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.